465 results on '"Sieper, Joachim"'
Search Results
2. Zur Rolle von HLA-B27 in der Pathogenese und Diagnostik der axialen Spondyloarthritis: 50 Jahre nach Entdeckung der starken genetischen Assoziation
3. Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
4. Geschichte der Biologikatherapie bei axialer Spondyloarthritis – Teil 2
5. Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on the progression of structural damage in the spine over 2 years in patients with radiographic axial spondyloarthritis from the randomised-controlled CONSUL trial.
6. Exploring complement biomarkers in suspected axial spondyloarthritis.
7. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial
8. Performance of the Ankylosing Spondylitis Disease Activity Score based on a quick quantitative C-reactive protein assay in patients with axial spondyloarthritis
9. Implementing an automated monitoring process in a digital, longitudinal observational cohort study
10. Deep learning for detection of radiographic sacroiliitis: achieving expert-level performance
11. Radiographic Progression in Sacroiliac Joints in Patients With Axial Spondyloarthritis: Results From a Five‐Year International Observational Study.
12. Association of nociplastic and neuropathic pain components with the presence of residual symptoms in patients with axial spondyloarthritis receiving biological disease-modifying antirheumatic drugs.
13. The unmet need in rheumatology: Reports from the targeted therapies meeting 2017
14. Goodbye to the term 'ankylosing spondylitis', hello 'axial spondyloarthritis': time to embrace the ASAS-defined nomenclature.
15. Axial spondyloarthritis
16. Associations de patients atteints de spondylarthrite ankylosante – quelles différences entre membres et non-membres ?
17. The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study
18. Ankylosing spondylitis self-help organisations – do members differ from non-members?
19. Incorporation of the anteroposterior lumbar radiographs in the modified Stoke Ankylosing Spondylitis Spine Score improves detection of radiographic spinal progression in axial spondyloarthritis
20. Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis.
21. Synovial cell production of IL-26 induces bone mineralization in spondyloarthritis
22. Comparing MRI and conventional radiography for the detection of structural changes indicative of axial spondyloarthritis in the ASAS cohort.
23. An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus
24. Do ethnicity, degree of family relationship, and the spondyloarthritis subtype in affected relatives influence the association between a positive family history for spondyloarthritis and HLA-B27 carriership? Results from the worldwide ASAS cohort
25. Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial
26. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA
27. Low Rate of Progression to Ankylosing Spondylitis Among Patients With Presumed Nonradiographic Axial Spondyloarthritis: Comment on the Article by Wang et al
28. Course of Magnetic Resonance Imaging–Detected Inflammation and Structural Lesions in the Sacroiliac Joints of Patients in the Randomized, Double-Blind, Placebo-Controlled Danish Multicenter Study of Adalimumab in Spondyloarthritis, as Assessed by the Berlin and Spondyloarthritis Research Consortium of Canada Methods
29. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
30. Diagnostic evaluation of the sacroiliac joints for axial spondyloarthritis: should MRI replace radiography?
31. Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort
32. Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis
33. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab
34. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis
35. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)
36. Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis*
37. Is Radiographic Axial SpA a Distinct Subset With More Severe Axial Involvement? Comment on the Article by Deodhar et al
38. Serum Adipokine Levels in Patients With Ankylosing Spondylitis and Their Relationship to Clinical Parameters and Radiographic Spinal Progression
39. Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial
40. Cytokine-induced human IFN-γ–secreting effector-memory Th cells in chronic autoimmune inflammation
41. MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group.
42. Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis.
43. Treatment With Tumor Necrosis Factor Inhibitors Is Associated With a Time‐Shifted Retardation of Radiographic Sacroiliitis Progression in Patients With Axial Spondyloarthritis: 10‐Year Results From the German Spondyloarthritis Inception Cohort
44. Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results.
45. Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis
46. The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administrationʼs Comments and Concerns
47. TNF signaling drives myeloid-derived suppressor cell accumulation
48. Relationship of bone mineral density with disease activity and functional ability in patients with ankylosing spondylitis: a cross-sectional study
49. Impaired Peripheral Th1 CD4+ T Cell Response to Escherichia coli Proteins in Patients with Crohn’s Disease and Ankylosing Spondylitis
50. Blockade of intra-articular adrenergic receptors increases analgesic demands for pain relief after knee surgery
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.